Juniper Biologics yakazivisa nhasi kuti yakawana kodzero dzerezinesi yekuvandudza nekutengesa TG-C LD (TissueGene-C yakaderera dosi) yekurapa mabvi osteoarthritis.
Iyo $600 miriyoni yeUSD rezenisi dhiri iyo inovhara Asia Pacific, Middle East neAfrica yakasainwa neKolon Life Science uye ndeye Juniper Biologics 'yechipiri kutora mumwedzi yakawanda. Pasi pemitemo yemubatanidzwa, Juniper Biologics ichava nebasa rekugadzira nekutengesa TG-C LD kune nyanzvi dzekurapa uye zvipatara mukati mematunhu aya. Kolon Life Science ichave nebasa rekutsigira budiriro pamwe nekupa TG-C LD.
TG-C LD mushonga wekuferefeta usiri wekuvhiya wakarumbidzwa senzira yekutanga pasi rose-mediated gene therapy ye osteoarthritis yemabvi,[i] inova nzira inonyanyozivikanwa yearthritis.[ii] Maererano netsvagiridzo, osteoarthritis inofungidzirwa kuva yegumi neimwe[1] inotungamirira chikonzero chekuremara pasi rose nevarwere vanofungidzirwa mamiriyoni 300 muAsia Pacific neMiddle East neAfrica chete, vachitambura nemigumisiro inopedza simba yehosha yemajoini. Ndicho chimwe chezvakakosha zvikuru zvekurapa zvinodiwa pakati pemisuloskeletal mamiriro ane njodzi inoratidzwa kuwedzera nezera[iii].
A first-in-class cell-mediated gene therapy, TG-C LD inotarisa mabvi osteoarthritis kuburikidza nejekiseni rimwe chete re-intra-articular. Kolon TissueGene, ane rezinesi reTG-C muUnited States (kwete TG-C LD), akatopedza chirongwa chekiriniki chechikamu chechipiri muUnited States, aine dhata rekutanga rinoratidza kuzorora kwakasimba uye kuvandudzwa kwekufamba mushure mejekiseni rimwe chete. mabvi akabatanidzwa, zvichida kusvika kumakore maviri. Phase 2 miedzo yekiriniki muUnited States inosanganisira varwere chiuru nemazana maviri irikuenderera mberi kuratidza kuchengetedzeka uye kushanda kweTG-C. Pamusoro pekusimbisa kuderedzwa kwakakosha kwemarwadzo uye kuvandudzwa kwebasa kunoonekwa kubva kuUS Phase 2 kliniki yekuedza, miedzo yakagadzirirwa kuratidza kunonoka kwechirwere kufambira mberi kuti uwane DMOAD (Chirwere Chinogadzirisa Osteoarthritis Drug).
Mukuru weJuniper Biologics, Raman Singh, akati: "Tinogara tichitsvaga kuona nzvimbo dzatinogona kuita mutsauko wakanyanya uye TG-C LD inopa zororo rakakura kune varwere vemabvi osteoarthritis vangangoda kuvhiyiwa kana dzimwe nzira dzekurapa. Takazvipira kupa marapirwo matsva ekurapa osteoarthritis yemabvi kuburikidza nekuvandudzwa kwecartilage uye tinotenda kuti iyi tsvakiridzo yekurapa ichaunza zororo kumamirioni evarwere mudunhu rese.
"Tinofara kushanda neJuniper Biologics kumisa nzira nyowani dzevarwere kuti vawane iyi itsva yekuferefeta cell therapy. Uku kungave kusimbiswa kwehunyanzvi hwedu uye kukosha kwayo pamusika, "akadaro Woosok Lee Mutungamiriri uye CEO, Kolon Life Science. "Tinotenda kuti varwere vemuAsia Pacific, Middle East neAfrica vachakwanisa kubatsirwa neTG-C LD apo isu tinofamba nekuoma kwekuimisa senzira yepasi rose yekurapa."
